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Summary: The objective of the present study was to characterize a commercially available immunoradiometric
assay (IRMA) intended for the determination of human insulin-like growth factor 1 (IGF-1) when used to determine
IGF-1 in canine plasma samples. The assay was evaluated by assessment of the precision, accuracy, and detection
limit, and by comparing the IGF-1 values observed in healthy dogs and in dogs with acromegaly and hereditary
pituitary dwarfism to values reported in the literature. Since extraction of IGF-1 from its binding proteins is essential
for reliable test results, the efficiency of the extraction method used in the assay was also examined.
The main conclusions can be summarized as follows: The commercially available IRMA method offers a precise
determination of the IGF-1 concentration in canine plasma samples with IGF-1 values directly comparable to those
obtained by others. The assay accuracy was confirmed for normal dogs by parallelity between IGF-1 concentrations
and plasma dilutions, whereas plasma from acromegalic dogs could not fullful parallelity. The detection limit was
below the IGF-1 concentrations observed in dogs with hereditary pituitary dwarfism. In plasma samples with low
or normal IGF-1 levels, the assay's extraction efficiency was comparable to that found using other extraction
methods. In samples with IGF-1 concentrations above usual physiological levels, the extraction efficiency decreased
unexplainably. However, this decrease in extraction efficiency seems to be of only minor importance when the
measurements are used in the diagnosis of canine acromegaly.
Introduction cessible assay for the determination of human IGF-1
~ . . ..... - - Λ . _— , (Diagnostic Systems Laboratories, Inc., Texas, USA;Canine insulin-like growth factor 1 (IGF-1, soma- 1 . * .... J . A '. T _ _ , n ',. -„ nvv . - , ., ... f DSL) could be used to measure canine IGF-1 as well. AtomedinC (1-^3)) is one of the peptides responsible for . . . . ,. , . _~ . . .
Α Λ? -. x· A ·/ -1 u \ A A major analytical problem when measunng IFG-1 is thethe effects of somatotropm (growth hormone), and de- :, . !r .
- . . , ι * Λ presence of strong molecular interactive forces betweenterminations of this component are used to evaluate the °
A _ . · ' * * · ' + u Λ- IGF-I and its binding proteins (e.g. 1, 2, 6). The prob-somatotropm status in dogs, for instance when diagnos- , . Λ/-Μ? ι ^ u 1 - 1 ·. , ,. . . , Ve , , 7A ex lem 1S managed by extraction of IGF-1 from the biologi-ing hereditary pituitary dwarfism and acromegaly (4,5). . ° . J ^ .J · · J cal material prior to analysis. Among the many ap-
Previously, canine IGF-1 was determined using assays proaches that have been used to obtain an effective and
not commercially available, thus restricting determina- reproducible extraction method, acidic column chroma-
tion of the peptide to specialized laboratories. We there- tography is generally considered to be the reference
fore decided to investigate whether a commercially ac- method (e. g. 7, 8). However, this method is laborious
and expensive, thus being less attractive for routine
7Γ7 ~ purposes. A recent comparison between different IGF-1
ProjecTna°lS6??-l of the Danish Agricultural and Veterinary extraction methods used on rat blood gave as result that
Research Council the best correlation to acidic column chromatography
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(8) was offered by acid-ethgnol cryoprecipitation; the
extraction recovery rates ranged from 76% to 80%. In
the IRMA method, extraction of IGF-1 was accom-
plished by acid-ethanol precipitation and a further objec-
tive of the present study was, therefore, to estimate the
efficiency of this extraction method to liberate canine
IGF-1 from its binding proteins.
herd dogs with hereditary pituitary dwarfism (9) to about 90 nmol/l
in acromegalic dogs (10), all results achieved using human JGF-1
for calibration. Thus, the kit's standards (1.17 to 52 nmol/l in the
preliminary and 0.65 to 78.0 nmol/l in the amended protocol, cal-
ibrated against the WHO reference 87/518) covered well the IGF-
1 levels usually found in dogs. IGF-1 concentrations were reported
in Si-units, i.e. nmol/l; to convert from "traditional" units (ng/
ml) to Si-units, multiply the number ίη "traditional" units by 0.13
(Mr = 7600).
Material and Methods
Collection of plasma samples for characterization of
the assay
The canine plasma samples used for characterization of the analysis
for IGF-1 were isolated from blood samples from clinically healthy
dogs and from hospitalized dogs of different breeds, ages and
sexes. Blood samples were also collected from female dogs suffer-
ing from acromegaly and from German Shepherd dogs suffering
from pituitary dwarfism. The diagnoses of acromegaly and pitu-
itary dwarfism were established by other means than determination
of IGF-1 (e.g., classical clinical signs, response to clonidine stimu-
lation test, response to glucose tolerance test, effect of ovariohys-
terectomy). The blood samples were obtained by puncture of a
jugular or cephalic vein and collected into heparinated vials (Vacu-
tainer®, Becton-Dickinson; USA). Plasma was isolated by centrifu-
gation of the blood samples (750 g for 5 min) immediately after
collection. Plasma samples were stored at -55 °C until analysis.
Analytical specificy
The DSL IGF-1 IRMA kit was reported to represent the following
cross-reactivities against human peptide hormones: IGF-1 100%;
insulin-like growth factor 2 (IGF-2) 3%; insulin, pro-insulin and
somatotropin not detectable. Data on cross-reactivity to canine pep-
tide hormones were not available. The cross-creactivity to canine
insulin was investigated by analysing various concentrations of
porcine insulin, since canine and porcine insulin have been re-
ported to be structurally identical (11).
Precision of the IGF-1 analysis
The intra-assay variation was monitored as the coefficient of varia-
tion (CV%) for the difference between single observations of dupli-
cates according to pooled-variance estimates at three IGF-1 con-
centrations (n = 14, 18, 7, respectively). The inter-assay variation
was recorded as the CV% for two control specimens analysed in
different assays (n = 5, 4, respectively).
Collection of plasma samples for estimation of the
inter- and int ra- individual coefficient of variation
Four unrelated male Beagle dogs (aged 2—3 years) and four unre-
lated female Labrador dogs (aged 1—2 years) were included in the
study. The dogs were all clinically healthy prior to and during the
study, and they had not received any medication for 3 weeks prior
to and throughout the study. The dogs were fasted 15 hours prior
to each collection of blood samples. Water was offered ad libitum
during the study.
Blood samples were collected between 8.30 and 9.30 a.m. at 7-
day intervals for 3 weeks. On each occasion, blood was collected
while care was taken not to excite the dogs in order to reduce any
effect from stress, handling and transport etc. Plasma was obtained
by <?entrifugation and stored as described above for no longer than
45 days. All samples were subjected to duplicate analysis in one
analytical run using the same set of reagents, calibrators and con-
trols.
Accuracy of the IGF-1 analysis
To assess the accuracy of the assay, various dilutions of plasma
samples from a healthy dog and from two acromegalic dogs,
respectively, were prepared by mixing with the kit's 0-standard,
since parallelity between dilution of samples and measured IGF-1
concentrations is likely to indicate that blood components do not
confound the assay system. The plasma dilutions were extracted
once according to the protocol suggested by the manufacturer and
subjected to analysis (n = 16 for each plasma specimen).
Limit of detection
The limit of detection, defined as the smallest single observation
which could be distinguished from zero, was calculated as the least
detectable concentration at a probability level of 0.05. A pooled-
variance estimate of low-IGF-1 samples (n = 9) was used to calcu-
late the standard deviation (SD) at concentration close to zero con-
centrations, and the limit of detection was calculated as 2.3 · SD.
Analysis for IGF-1 in canine plasma
The analysis for IGF-1 in canine plasma was performed with a
commercial IRMA designed for determination of human IGF-1
(DSL; preliminary protocol of 20/10/93 and amended protocol of
19/09/94). The kit is a sandwich-type solid phase immunoradiome-
tric assay with anti-human IGF-1 antibody immobilised to the wall
of test tubes in which standard human IGF-1 amounts (0 to approx-
imately 78 nmol/l) and sample extracts were incubated together
with 125I-labelled anti-human IGF-1 antibody. Following decanta-
tion and washing, the bound tracer was quantified by counting in
a γ-counter for 60 s. Samples were prepared for analysis by extrac-
tion with four volumes of the kit's extraction solution, which con-
sisted of 2.0 mol/1 HC1, volume fraction 0.125 in absolute ethanol.
This method was reported in the protocol to recover 90-100% of
added IGF-1 from human blood. The dilution factor between blood
concentration and concentration of IGF-1 in the assay was 15.
Previous investigations have reported that the plasma IGF-1 con^
centration in dogs ranged from about 1 nmol/l for German Shep-
Investigation of extraction efficiency
Plasma samples used for the investigation of assay accuracy were
subjected to repeated acid-ethanol precipitation (four times totally)
in order to estimate the total IGF-1 content of the material. The
3rd and the 4th extraction did not show measurable amounts of
IGF-1 and were therefore excluded from the subsequent calcula-
tions: in order to quantify the extraction efficiency, the ratio of
the IGF-1 concentration obtained following the first extraction was
calculated relative to the estimated total IGF-1 concentration.
Statistical methods
Descriptive statistics, correlation between sample dilution and
measured IGF-1 using untransformed data and logarithmically
transformed data, performance of lack-of-fit test (LOF test) were
calculated as previously described (12, 13).
Fr ser & Harris (14) have proposed that the maximum value of
a! is half the intra-individual Coefficient of variance (i. e.,
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!/2 · CV%intra) when the analysis is used to aid in diagnosis or to
monitor therapy by single or serial testing in one individual,
CV%intra was calculated as previously described (14, 15) using the
entire set of test results from the 4 Beagles and 4 Labradors over
the 3 weeks period.
Results
Specificity
The cross-reactivity to canine insulin Was insignificant
at blood concentrations up to 12.5 μηιοΐ/ΐ. In terms of
linear regression, (x, y) = (added insulin, measured
IGF-1): y = 0.04163 -0.008395 X added insulin,
P( i = 0) = 0.07, n = 18, r = -0.4375, n = 18.
Precision
The intra- and inter-assay CV% at different IGF-1 con-
centrations are presented in table 1. Intra-assay CV%
ranged between 6% and 10%, and the inter-assay CV%
was around 10%.
different from unity (p = 0.72). In contrast, the dilution
curve derived from plasma from two acromegalic dogs
did not fit a straight-line model properly (p(LOF)
< 0.0001), neither when untransformed nor logarithmi-
cally transformed data were correlated. The curve for
dilution of extracts from acromegalic dogs did not ap-
pear straight-lined, either (p(LOF) < 0.0001).
Estimation of the inter- and int ra- individual
coefficient of var ia t ion
From the results of the 4 Beagles and 4 Labradors, the
total variance (Sxotai) was estimated as 78.2, the inter-
individual variance (S?nter) as 63.9, the intra-individual
variance (Simra) as 12.7, and the analytical variance
($Αηαΐ.) as 1.6. The overall mean IGF-1 concentration
was calculated as 17.0 ± 2.9 nmol/1. Based on these
components of variance and the overall mean value,
CV%,ntra was calculated as 21.0%, and CV%Anal> was
calculated as 7.4%. Hence, the maximum value for
CV%Anal. was 10.5% for individual testing.
Accuracy
IGF-1 concentrations were measured in various dilutions
of plasma samples from a healthy and two acromegalic
dogs, respectively (n = 4 for each of 4 dilutions per
dog). Also, extracts of acromegalic plasma samples were
diluted and subsequently assayed. The results, outlined
in figure 1 and table 2, show that the dilution curve
derived from plasma of a healthy dog appeared as a
straight line since a test for model fitting was non-signif-
icant (p(LOF) = 0.53). Following logarithmic trans-
formation it could be shown that there existed propor-
tionality between the measured amount of IGF-1 and
the degree of dilution as evidenced by the straight-line
relationship (p(LOF) = 0.40) together with a slope not
Tab. 1 Intra- and inter-assay coefficient of variation of the deter-



































a number of observations;
b standard deviation;
c CV coefficient of variation;
d calculated from a pooled-variance estimate of differences be-
tween duplicate determinations at three IGF-1 concentrations;
c calculated from means of duplicates at two IGF-1 concentrations.
Limit of detection
The limit of detection was calculated as 0.2 nmol/1 (SD
0.1 nmol/1), thus depicting a least detectable concentra-
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Sample dilution
Fig. 1 The IGF-1 concentration following dilution of plasma
samples from a healthy dog (solid line), two acromegalic dogs
(dotted lines), and dilutions of extract of plasma from an acrome-
galic dog (dashed line). The samples were diluted with the 0-stan-
dard supplied with the commercially availably IRMA kit. SEM
(error bar) is the standard error on the mean.
Clin Chem Clin Biochem 1995; 33 (No 12)
942 Jensen and H0ier: Determination of canine IGF-1
plasma from healthy dogs and below the IGF-1 concen-
trations observed in the German Shepherd dogs with he-
reditary pituitary dwarfism, albeit close.
IGF-1 levels in heal thy dogs and in dogs
suffering from acromegaly and dwarfism
The plasma IGF-1 concentrations as determined by the
employed method in healthy dogs, in dogs with acro-
megaly, and in dogs with hereditary pituitary dwarfism
are shown in table 3.
Extraction efficiency
The ratios of the IGF-1 concentration following the first
extraction to the estimated total IGF-1 concentration are
summarized in figure 2, and it can be seen that plasma
specimens with different IGF-1 concentrations were ex-
tracted in different ways. Using plasma samples from a
healthy dog, the ratio averaged 0.84 (corresponding to
an extraction efficiency of 84%), and dilution of the
samples did not affect the extraction recovery signifi-
cantly (p(slope = 0) = 0.10 in linear regression). In the
samples from acromegalic dogs, however, the ratio
ranged from 0.73 to 0.85, the lowest ratio being ob-
served in extracts of undiluted plasma.
Discussion
Although the amino acid sequence of canine IGF-1 is
not known at present, the antibody against human IGF-1
used in this study cross-reacted with canine IGF-1, since
the assay clearly detected the decreased IGF-1 levels
expected to be found in dogs with hereditary pituitary
dwarfism and the expected augmented IGF-1 levels in
acromegalic dogs. The close interspecies similarity with
respect to the structure of IGF-1 found in this study is
in agreement with the previously reported high degree
of conservation of IGF-1 structure (2) and is further sup-
ported by the fact that previously published methods for
measurement of canine IGF-1 were all evaluated by use
of antibodies directed against human IGF-1, and using
human IGF-1 for calibration and tracer preparation (9,
10, 16).
The specificty of the analysis could not be fully investi-
gated due to the scarce supply of canine IGF varieties.
However, we analysed the cross-reactivity to canine in-
sulin by measuring the response from porcine insulin,
since identity between beteen canine and porcine insulin
has previously been reported (11). The analysis appeared
to be specific since no response could be detected from
insulin concentrations up to 12.5 μιηοΐ/ΐ in the blood.
The findings presented in table 1 show that the concen-
tration of IGF-1 in canine plasma samples can be pre-
cisely measured with intra- and inter-assay coefficients
of variation within acceptable ranges at IGF-1 concen-
trations expected be found in dogs. The intra- and inter-
assay CV% of the present study were acceptable when
compared to methods involving both extraction and ana-
lytical variation; thus, Eigenmann et al. (10) reported
intra- and inter-assay variation for the determination of
IGF-1 in dogs to be 16.7% and 21.7%, respectively. The
limit of detection of the assay (0.2 ninol/1) was well
below the IGF-1 concentrations commonly observed in
healthy dogs, and also lower than the IGF-1 concentra-
tions in dogs with hereditary pituitary dwarfism.
The accuracy of the analysis (fig. 1) was outlined as
the presence of parallelism between dilutions of plasma
samples from a healthy dog and the measured concentra-
tions of IGF-1. This finding is in agreement with the
amended protocol of the kit which claims proportional-
ity between degree of dilution and results of analysis if
diluted samples are extracted and analyzed or if ex-
tracted sample is diluted and analyzed, when normal hu*
man plasma samples are investigated. Plasma samples
from acromegalic dogs, however, did not depict paral-
lelism between degree of dilution and measured concen-
Tab. 2 Accuracy of the IGF-1 assay: Regression analyses of untransformed (linear) and logarithmically



































a number of observations;
b intercept of the regression line;
c the slope of regression line;
d coefficient of correlation;
c the probability of fitting to the straight line model;
f the probability of the slope being equal to unity;
ε plasma sample from a healthy dog;
h plasma samples from two acromegalic dogs.
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tration of IGF-1; the kit's protocol does not describe
dilution curves from samples from acromegalic individ-
uals. It could be argued that the dilution of plasma with
the kit's 0 standard merely dilutes the strongly attached
IGF-1 : IGF-1 binding protein (IGFBP-3) complexes,
and therefore a skewed dilution curve might be expected
due to dissociation of the complexes. Meanwhile, this is
contradicted by the fact that the dilution curve from the
healthy dog expressed linearity between degree of dilu-
tion and the measured IGF-1 concentration. As indicated
in figure 2, the reason for this discrepancy might be a
Tab. 3 Plasma IGF-1 concentrations in healthy dogs, in dogs suf-
























a number of observations;
b highest and lowest IGF-1 concentration measured;
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Fig. 2 Efficiency of the extraction method used in the IRMA
method (acid-ethanol precipitation) to liberate IGF-1 from its bind-
ing proteins in plasma samples from a healthy dog (solid line) and
an acromegalic dog (dotted line) in various dilutions. The extrac-
tion efficiency is depicted as the rate of the IGF-1 concentration
following the first extraction to the estimated total IGF-1 concen-
tration in the samples. The total IGF-1 concentration in the samples
was estimated as the total amount of IGF-1 measured during 4
extractions. The 0-standard supplied with the assay was used as
diluent. SEM (error bar) is the standard error on the mean.
less effective extraction of very high concentrations of
IGF-1 (see below). It could also be argued that both
extraction rate and accuracy of the assay could be inves-
tigated more precisely by extraction and analysis of
samples to which known amounts of IGF-1 were added.
However, purified canine IGF-1 is scarce. In addition,
samples constructed by addition of IGF-1 but not IGF-1
binding proteins might release IGF-1 more easily during
extraction due to shortage of binding proteins, thereby
confounding the extraction efficiency.
The estimates of the inter- and intra-individual plus ana-
lytical components of variance further supported the
clinical usefulness of the assay, the analytical variance
(CV = 7.4%) being lower than the maximum tolerable
values (10.5%) estimated from the various components
of variance.
The extraction efficiency (73%-85%) of the acid-etha-
nol precipitation used in this study is comparable with
those previously reported, which ranged from 79% (8)
to 93% (16). In the present study, the extraction effi-
ciency was about 85% for plasma from healthy dogs,
while the efficiency was lower, approximately 73%, for
undiluted plasma samples from acromegalic dogs. Sev-
eral explanations may account for this discrepancy:
Firstly, our estimates of the total IGF-1 concentration
are based on the assumption that it is possible to release
all IGF-1 from its binding proteins by repeated extrac-
tions.
Secondly, it may be that the concentrations of the vari-
ous IGF-1 binding proteins in acromegalic dogs are of
importance. For instance, IGFBP-3 (e.g. 1) is probably
primarily regulated by somatotropin (6, 17), and it is
likely that in canine acromegaly, the progestin-induced
somatotropin excess originating from the mammary
gland (18), besides inducing an increase in the plasma
IGF-1 level (19) also induces an increase in IGFBP-3.
If this hypothesis is true, an excess of IGFBP-3 in the
blood from acromegalic dogs might inhibit the release
of IGF-1 during extraction.
Thirdly, a carry-over of IGFBP-3 during extraction
would be expected to disturb the binding of IGF-1 to
the antibody during the assay, and in fact the non-linear
curve found after dilution of extracted acromegalic ma-
terial indicates that the analysis for IGF-1 might be af-
fected significantly by material extracted from the
blood. However, this hypothesis is contradicted by the
straight-line recoveries seen from analysis of plasma
from a normal dog, unless the profile and effect of the
IGF-1 binding proteins are altered during acromegaly.
Differences might exist between the tertiary structures
of human and canine IGF-1, and therefore, the affinity
of the antibody against canine IGF-1 might be lower
Eur J Clin Chem Clin Biochem 1995; 33 (No 12)
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than the affinity for human IGF-1, although this expla-
nation is not in agreement with the linear relationship
between degree of dilution of measured IGF-1 in
blood from a normal dog. However, if the latter hy-
pothesis is true, the decrease in extraction rate seen
in undiluted or slightly diluted plasma from an acro-
megalic dog, besides being an indication of differences
between human and canine IGF-1, is an underestima-
tion of high IGF-1 concentrations rather than a
decrease in extraction rate. The problem concerning
dilution of material from acromegalic individuals
awaites further investigation.
Despite the reduced extraction efficiency at high IGF-1
levels, the assay still generates IGF-1 values that are
directly comparable to those reported earlier. For Ger-
man Shepherd dogs with hereditary pituitary dwarfism,
Eigenmann et al. (9) reported a plasma IGF-1 level of
1.5 ± 0.3 nmol/1 (mean ± SEM), while in the present
study the level was 1.0 ± 0.4 nmol/1. In healthy dogs,
the plasma IGF-1 level depends on various factors such
as breed, age, and body size (10, 20) and therefore, spe-
cific reference ranges are difficult to obtain. However,
the healthy adult Beagles and Labradors used in the pre-
sent study had a mean plasma IGF-1 concentration of
17.0 ± 2.9 nmol/1, a value that is comparable to the IGF-
1 levels found by Eigenmann et al. (10) in healthy, adult
Beagles (11.3 ± 4.3 nmol/1) and Kesshonds (15.2 ± 4.4
nmol/1). The mean plasma IGF-1 concentration of the 7
acromegalic dogs in the present study (46.8 ± 8.1
nmol/1) is lower than reported by Eigenmann et al. (19)
for 29 acromegalic dogs of different breeds (91.0 ± 11.7
nmol/1). Part of this discrepancy might be accounted for
by the decreased extraction rate found in this study.
Thus, if the IGF-1 concentrations in acromegalic dogs
were measured following an initial 2-fold dilution of the
samples due to expectations of values exceeding the cal-
ibrator range, our mean concentration for acromegalic
dogs would have been above 60 nmol/1, a value which
is much closer to the level reported by Eigenmann et
al. (10).
In summary, the commercial IRMA method used in the
present study can be used to measure the plasma IGF-1
concentration in dogs, and it generates IGF-1 concentra-
tions that are directly comparable to those obtained by
other methods. The measurements are precise, at least
for normal dogs and dogs suffering from pituitary
dwarfism. In addition, the method fulfills current de-
mands to the analytical variance when compared to the
biological variation. Except for plasma IGF-1 concentra-
tions above the physiological level, the assay's effi-
ciency in extracting IGF-1 from its binding proteins is
comparable to that found when using other methods. In
plasma samples with higher IFG-1 concentrations, the
assay's extraction efficiency decreases unexplainably.
This deviance in extraction efficiency appears, however,
to be of minor importance for the diagnosis of canine
growth hormone abnormalities.
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